Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
16.71
USD
|
+2.45%
|
|
-0.65%
|
-46.63%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,589
|
8,499
|
3,752
|
2,578
|
5,140
|
2,761
|
-
|
-
|
Enterprise Value (EV)
1 |
5,892
|
7,867
|
3,231
|
2,161
|
4,702
|
2,154
|
1,897
|
1,455
|
P/E ratio
|
-26.7
x
|
-29.9
x
|
-22.2
x
|
-11.9
x
|
-84.6
x
|
26.6
x
|
12.8
x
|
9.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.4
x
|
19.2
x
|
7.75
x
|
4.98
x
|
7.08
x
|
2.85
x
|
2.54
x
|
2.23
x
|
EV / Revenue
|
17.4
x
|
17.8
x
|
6.67
x
|
4.18
x
|
6.47
x
|
2.23
x
|
1.74
x
|
1.18
x
|
EV / EBITDA
|
-24.2
x
|
-27.7
x
|
-19.3
x
|
-9.75
x
|
-69.3
x
|
20.7
x
|
8.4
x
|
3.73
x
|
EV / FCF
|
-38.7
x
|
-54.7
x
|
-25.5
x
|
-19
x
|
282
x
|
20.4
x
|
7.78
x
|
3.88
x
|
FCF Yield
|
-2.58%
|
-1.83%
|
-3.92%
|
-5.28%
|
0.35%
|
4.89%
|
12.9%
|
25.7%
|
Price to Book
|
9.5
x
|
13.6
x
|
6.95
x
|
6.44
x
|
11.9
x
|
4.54
x
|
3.01
x
|
2.12
x
|
Nbr of stocks (in thousands)
|
154,025
|
158,978
|
160,756
|
161,931
|
164,180
|
165,203
|
-
|
-
|
Reference price
2 |
42.78
|
53.46
|
23.34
|
15.92
|
31.31
|
16.71
|
16.71
|
16.71
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
339.1
|
441.8
|
484.1
|
517.2
|
726.4
|
967.2
|
1,089
|
1,238
|
EBITDA
1 |
-243.8
|
-283.7
|
-167.1
|
-221.6
|
-67.83
|
104.2
|
225.8
|
389.7
|
EBIT
1 |
-246.5
|
-286.6
|
-170.4
|
-223.6
|
-73.38
|
106.6
|
215.4
|
334
|
Operating Margin
|
-72.71%
|
-64.87%
|
-35.2%
|
-43.23%
|
-10.1%
|
11.02%
|
19.78%
|
26.97%
|
Earnings before Tax (EBT)
1 |
-234.4
|
-281
|
-167.5
|
-213.4
|
-51.04
|
109.1
|
232.3
|
347.1
|
Net income
1 |
-235.3
|
-281.6
|
-167.9
|
-216
|
-61.29
|
109.6
|
220.9
|
321.5
|
Net margin
|
-69.38%
|
-63.74%
|
-34.67%
|
-41.76%
|
-8.44%
|
11.33%
|
20.29%
|
25.96%
|
EPS
2 |
-1.600
|
-1.790
|
-1.050
|
-1.340
|
-0.3700
|
0.6288
|
1.302
|
1.819
|
Free Cash Flow
1 |
-152.3
|
-143.8
|
-126.8
|
-114
|
16.65
|
105.4
|
244
|
374.7
|
FCF margin
|
-44.9%
|
-32.54%
|
-26.19%
|
-22.05%
|
2.29%
|
10.9%
|
22.41%
|
30.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
101.16%
|
108.05%
|
96.15%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
96.2%
|
110.46%
|
116.54%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
131.6
|
130.8
|
115.5
|
134.6
|
130.7
|
136.5
|
118.5
|
165.2
|
211.7
|
231
|
208.7
|
242
|
254.3
|
261.7
|
221.1
|
EBITDA
1 |
-13.73
|
-44.12
|
-112.1
|
-33.04
|
-30.36
|
-45.57
|
-53.16
|
4.803
|
-56.05
|
36.58
|
10.08
|
34.59
|
42.04
|
22.49
|
-
|
EBIT
1 |
-15.3
|
-44.66
|
-113
|
-33.65
|
-30.87
|
-46.06
|
-53.58
|
3.037
|
-57.78
|
34.94
|
6.291
|
33.11
|
38.23
|
30.98
|
59.7
|
Operating Margin
|
-11.63%
|
-34.15%
|
-97.88%
|
-25.01%
|
-23.61%
|
-33.75%
|
-45.23%
|
1.84%
|
-27.29%
|
15.12%
|
3.01%
|
13.68%
|
15.03%
|
11.84%
|
27%
|
Earnings before Tax (EBT)
1 |
-14.79
|
-42.9
|
-112.6
|
-33.57
|
-26.42
|
-40.89
|
-44.94
|
6.343
|
-52.14
|
39.7
|
9.107
|
35.79
|
35.79
|
27.49
|
59.7
|
Net income
1 |
-14.46
|
-43.09
|
-113.1
|
-34.01
|
-27.18
|
-41.72
|
-43.02
|
1.114
|
-65.18
|
45.8
|
8.071
|
34.4
|
34.72
|
27.73
|
47.2
|
Net margin
|
-10.98%
|
-32.96%
|
-97.91%
|
-25.28%
|
-20.8%
|
-30.57%
|
-36.32%
|
0.67%
|
-30.79%
|
19.82%
|
3.87%
|
14.22%
|
13.65%
|
10.59%
|
21.35%
|
EPS
2 |
-0.0900
|
-0.2700
|
-0.7000
|
-0.2100
|
-0.1700
|
-0.2600
|
-0.2700
|
0.0100
|
-0.4000
|
0.2800
|
0.0552
|
0.1918
|
0.1994
|
0.1702
|
0.2800
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
2/28/22
|
5/4/22
|
8/8/22
|
11/2/22
|
2/27/23
|
5/8/23
|
8/2/23
|
11/2/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
697
|
632
|
521
|
417
|
439
|
606
|
864
|
1,305
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-152
|
-144
|
-127
|
-114
|
16.7
|
105
|
244
|
375
|
ROE (net income / shareholders' equity)
|
-39.9%
|
-42.5%
|
-28.7%
|
-45.9%
|
-14.7%
|
22%
|
28.7%
|
27.8%
|
ROA (Net income/ Total Assets)
|
-35.6%
|
-36%
|
-22.6%
|
-33.5%
|
-9.17%
|
16.4%
|
25.9%
|
15.6%
|
Assets
1 |
661.7
|
782.9
|
741.4
|
644
|
668.4
|
668.9
|
853.1
|
2,060
|
Book Value Per Share
2 |
4.500
|
3.930
|
3.360
|
2.470
|
2.640
|
3.680
|
5.550
|
7.880
|
Cash Flow per Share
2 |
-1.030
|
-0.8700
|
-0.7800
|
-0.7100
|
0.1000
|
1.070
|
1.310
|
3.560
|
Capex
1 |
1.13
|
7.59
|
1.12
|
-
|
0.05
|
3.14
|
2.78
|
2.03
|
Capex / Sales
|
0.33%
|
1.72%
|
0.23%
|
-
|
0.01%
|
0.32%
|
0.25%
|
0.16%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
16.71
USD Average target price
29.09
USD Spread / Average Target +74.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -46.63% | 2.76B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|